Admedus: Solid 3QFY15 result
![](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ3dDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--72a5fdcb8549c0252d373a251befaa725e13a1bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lKYW5CbFp3WTZCa1ZVT2hOeVpYTnBlbVZmZEc5ZlptbHNiRnNIYVFISWFRSEkiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--a788536266c8d052a67a95e113f2ebbff3ad0a97/34555966e256f39eefafa6eb2f711a721425616712.png)
Morgans
Admedus (AHZ, Add, Price Target A$0.20) AHZ posted a solid 3QFY15 result with revenue up 47% to A$2.4m. We estimate the key CardiolCel® sales were approximately A$800,000 with now over 60 centres in US and Europe using the device. Following the recent capital raising, AHZ is well funded and a number of key catalysts over the coming quarters will likely see the share price recover from the current levels. Add maintained. Report attached
1 topic
1 stock mentioned
![Scott Power](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ3dDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--72a5fdcb8549c0252d373a251befaa725e13a1bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lKYW5CbFp3WTZCa1ZVT2hOeVpYTnBlbVZmZEc5ZlptbHNiRnNIYVFISWFRSEkiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--a788536266c8d052a67a95e113f2ebbff3ad0a97/34555966e256f39eefafa6eb2f711a721425616712.png)
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
![Scott Power](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ3dDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--72a5fdcb8549c0252d373a251befaa725e13a1bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lKYW5CbFp3WTZCa1ZVT2hOeVpYTnBlbVZmZEc5ZlptbHNiRnNIYVFISWFRSEkiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--a788536266c8d052a67a95e113f2ebbff3ad0a97/34555966e256f39eefafa6eb2f711a721425616712.png)
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise